Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Extends Alnylam RNAi Rx Partnership for Fifth Year


Alnylam Pharmaceuticals last week announced that Novartis has decided to extend the companies' RNAi therapeutics collaboration for a fifth year, the last under the terms of the deal, through October 2010.

The deal was first announced in Sept. 2005, and called for Alnylam to optimize certain of Novartis' lead RNAi drug candidates, which Novartis would develop and commercialize (see RNAi News, 9/9/2005).

The deal had an initial three-year term, but included the option for Novartis to extend it for two additional one-year periods.

In addition to paying Alnylam upfront fees, research funding, and milestones, Novartis purchased what was then 19.9 percent of the RNAi drug shop's equity. That stake currently stands at around 13.4 percent, according to Alnylam.

"We are thrilled that Novartis has once again elected to extend our alliance, this time for a fifth and final planned year," Alnylam CEO John Maraganore said in a statement. "This is the second extension that Novartis has elected to make, which we believe reflects the success of our collaborative efforts as well as the scientific progress we have made in advancing our innovative technology to patients."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.